Equity · Healthcare
ARWR
NASDAQArrowhead Pharmaceuticals (ARWR)
The line runs 86.78 USD on 24 August through 41.39 USD on 20 November, on a scale from 40 to 100. Days the market did not trade hold the previous close, flat.
- Market cap
- 5.9B USD
- Revenue, year to Sep 2026
- 450.8M USD
- EPS, diluted, year to Sep 2026
- −5.11 USD
- 52-week range
- 38.09 USD – 89.61 USD
- Avg volume
- 132.4K
as of Nov 20, 2026
Have Arrowhead Pharmaceuticals (ARWR) insiders bought or sold shares recently?
ARWR's newest Form 4 filing is dated 18 August 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 18 Aug 2026 | OLUKOTUN ADEOYE YDirector | Sell | 2,000 | 174K USD |
| 18 Aug 2026 | PERRY MICHAEL SDirector | Sell | 11,600 | 1.0M USD |
| 12 May 2026 | Lu HongboDirector | Sell | 2,970 | 228K USD |
| 23 Apr 2026 | Hamilton James CChief Medical Officer | Sell | 10,000 | 750K USD |
| 22 Apr 2026 | Apel Daniel JosephChief Financial Officer | Sell | 13,095 | 934K USD |
| 05 Mar 2026 | Hamilton James CChief Medical Officer | Sell | 10,000 | 642K USD |
| 05 Jan 2026 | O'Brien PatrickCOO | Sell | 49,493 | 3.1M USD |
| 05 Jan 2026 | Hamilton James CChief Medical Officer | Sell | 40,164 | 2.5M USD |
| 02 Jan 2026 | Anzalone Christopher RichardChief Executive Officer | Sell | 13,187 | 872K USD |
| 29 Dec 2025 | Anzalone Christopher RichardChief Executive Officer | Sell | 51,726 | 3.6M USD |
| 26 Dec 2025 | Ferrari MauroDirector | Sell | 7,530 | 527K USD |
| 22 Dec 2025 | Anzalone Christopher RichardChief Executive Officer | Sell | 12,586 | 861K USD |
| Sold | 21 open-market sales | 560,501 | $37.34M |
Showing the 12 most recent of 21 open-market trades in this window. The figures above count all of them.
15 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Jun 2026 | Cohen Matthew GregoryDirector | Award | 11,882 | |
| 06 Jan 2026 | O'Brien PatrickCOO | Gift | 2,500 | |
| 06 Jan 2026 | O'Brien PatrickCOO | Award | 75,000 | |
| 06 Jan 2026 | Hamilton James CChief Medical Officer | Award | 75,000 | |
| 06 Jan 2026 | Apel Daniel JosephChief Financial Officer | Award | 75,000 | |
| 31 Dec 2025 | O'Brien PatrickCOO | Gift | 2,800 | |
| 29 Dec 2025 | Anzalone Christopher RichardChief Executive Officer | Option exercise | 51,726 | 318K USD |
| 16 Dec 2025 | INGRAM DOUGLAS SDirector | Award | 7,819 | |
| 16 Dec 2025 | OLUKOTUN ADEOYE YDirector | Award | 7,819 | |
| 16 Dec 2025 | PERRY MICHAEL SDirector | Award | 7,819 | |
| 16 Dec 2025 | Ferrari MauroDirector | Award | 7,819 | |
| 16 Dec 2025 | Waddill William D.Director | Award | 7,819 |
Showing the 12 most recent of 15 compensation filings in this window. The figures above count all of them.
Which funds hold Arrowhead Pharmaceuticals (ARWR)?
12 of the 45 institutional funds we track reported a Arrowhead Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 383.0M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Held (±25%) | 1,709,053 | 111.9M USD | −14.2% |
| Two Sigma Investments | Added | 1,083,432 | 70.9M USD | +86.6% |
| Fisher Asset Management | Held (±25%) | 893,700 | 58.5M USD | −6.7% |
| Balyasny Asset Management | Added | 695,883 | 45.5M USD | +47.8% |
| Millennium Management | Added | 497,587 | 32.6M USD | +51.1% |
| Marshall Wace | Held (±25%) | 306,491 | 20.1M USD | +0.5% |
| AQR Capital Management | Held (±25%) | 213,582 | 14.0M USD | +7.4% |
| Citadel Advisors | New position | 197,656 | 12.9M USD | |
| D. E. Shaw & Co. | Trimmed | 158,719 | 10.4M USD | −63.2% |
| Man Group | New position | 51,106 | 3.3M USD |
Showing the 10 largest of 12 reported positions. The figures above count all of them.
Have members of Congress traded Arrowhead Pharmaceuticals (ARWR)?
The most recent congressional trade disclosed in Arrowhead Pharmaceuticals is a sale by Daniel S. Goldman (house, NY), dated 31 Jan 2023.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 31 Jan 2023 | Daniel S. Goldmanhouse · Democrat–NY | Sale | 1K USD–15K USD | 24 days |
What has been filed or recorded for Arrowhead Pharmaceuticals (ARWR)?
The filings we hold for Arrowhead Pharmaceuticals, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 08 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 540 shares | 33K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Annual report | FY 2026 reported | EPS −5.11 USD | |
| 30 Sep 2026 | Financials | Revenue | 450.8M USD | fiscal year |
| 30 Sep 2026 | Financials | Net income | −724.2M USD | fiscal year |
| 30 Sep 2026 | Financials | Diluted EPS | −5.11 USD | fiscal year |
| 30 Sep 2026 | Financials | Total assets | 1.7B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 50.3M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.36 USD | |
| 31 Mar 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.93 USD | |
| 31 Dec 2025 | Quarterly earnings | Q1 2026 reported | EPS 0.22 USD | |
| 30 Sep 2025 | Annual report | FY 2025 reported | EPS −0.01 USD | |
| 30 Jun 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.26 USD | |
| 31 Mar 2025 | Quarterly earnings | Q2 2025 reported | EPS 2.75 USD | |
| 31 Dec 2024 | Quarterly earnings | Q1 2025 reported | EPS −1.39 USD |
What do people ask about Arrowhead Pharmaceuticals (ARWR)?
What did Arrowhead Pharmaceuticals shares close at?41.39
Arrowhead Pharmaceuticals closed at 41.39 USD on 20 Nov 2026, down 5.13% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Arrowhead Pharmaceuticals’ market cap?5.9B
Arrowhead Pharmaceuticals is worth 5.9B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Arrowhead Pharmaceuticals’ revenue?450.8M
Arrowhead Pharmaceuticals reported revenue of 450.8M USD for the year ended 30 Sep 2026, as filed with the SEC. See Filings
Have Arrowhead Pharmaceuticals insiders bought or sold shares recently?
No Arrowhead Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 18 Aug 2026 (SEC Form 4). See Insiders
Which funds own Arrowhead Pharmaceuticals?12 of 45
12 of the 45 funds we track reported a Arrowhead Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Two Sigma Investments and Fisher Asset Management. See Funds
Have members of Congress traded Arrowhead Pharmaceuticals?1 trade
Yes. 1 trade in Arrowhead Pharmaceuticals appears in the congressional disclosures we hold: a sale by Daniel S. Goldman (House, NY) dated 31 Jan 2023, filed 24 Feb 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Arrowhead Pharmaceuticals last report earnings?−5.11
Arrowhead Pharmaceuticals last reported earnings on 30 Sep 2026 for FY 2026, with EPS of −5.11 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Daniel S. Goldman: US House, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words